Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present)

References

• Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Ann Rev Biochem. 2010;79:181–211.
   PubMed Web of Science ®Google Scholar
• Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40(2):179–204.
   PubMed Web of Science ®Google Scholar
• Chang HHY, Pannunzio NR, Adachi N, et al. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol. 2017;18(8):495–506.
   PubMed Web of Science ®Google Scholar
• O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547–560.
   PubMed Web of Science ®Google Scholar
• Hartley KO, Gell D, Smith GC, et al. DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product. Cell. 1995;82(5):849–856.
   PubMed Web of Science ®Google Scholar
• Lempiäinen H, Halazonetis TD. Emerging common themes in regulation of PIKKs and PI3Ks. Embo J. 2009;28(20):3067–3073.
   PubMed Web of Science ®Google Scholar
• Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: the Trinity at the Heart of the DNA Damage Response. Mol Cell. 2017;66(6):801–817.
   PubMed Web of Science ®Google Scholar
• Goodwin JF, Knudsen KE. Beyond DNA repair: DNA-PK function in cancer. Cancer Discov. 2014;4(10):1126–1139.
   PubMed Web of Science ®Google Scholar
• Smith GC, Jackson SP, The DN. A-dependent protein kinase. Genes Dev. 1999;13(8):916–934.
   PubMed Web of Science ®Google Scholar
• Hill R, Lee PW. The DNA-dependent protein kinase (DNA-PK): more than just a case of making ends meet? Cell Cycle. 2010;9(17):3460–3469.
   PubMed Web of Science ®Google Scholar
• Kastan MB. DNA damage responses: mechanisms and roles in human disease: 2007 G.H.A. Clowes memorial award lecture. Mol Cancer Res. 2008;6(4):517–524.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Lu H, Zhu S, et al. Activation of EGFR-DNA-PKcs pathway by IGFBP2 protects esophageal adenocarcinoma cells from acidic bile salts-induced DNA damage. J Exp Clin Cancer Res. 2019;38(1):13.
   PubMedGoogle Scholar
• Evert M, Frau M, Tomasi ML, et al. Deregulation of DNA-dependent protein kinase catalytic subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value. Br J Cancer. 2013;109(10):2654–2664.
   PubMed Web of Science ®Google Scholar
• Cornell L, Munck JM, Alsinet C, et al. DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival. Clin Cancer Res. 2015;21(4):925–933.
   PubMed Web of Science ®Google Scholar
• Pilié PG, Tang C, Mills GB, et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16(2):81–104.
   PubMed Web of Science ®Google Scholar
• Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020;5(1):60.
   PubMed Web of Science ®Google Scholar
• Lu H, Saha J, Beckmann PJ, et al. DNA-PKcs promotes chromatin decondensation to facilitate initiation of the DNA damage response. Nucleic Acids Res. 2019;47(18):9467–9479.
   PubMed Web of Science ®Google Scholar
• Lee HS, Yang HK, Kim WH, et al. Loss of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in gastric cancers. Cancer Res Treat. 2005;37(2):98–102.
   PubMedGoogle Scholar
• Abdel-Fatah TM, Arora A, Moseley P, et al. ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers. BBA Clin. 2014;2:10–17.
   PubMedGoogle Scholar
• Doherty RE, Bryant HE, Valluru MK, et al. Increased non-homologous end joining makes DNA-PK a promising target for therapeutic intervention in uveal melanoma. Cancers (Basel). 2019;11(9):1278.
   Web of Science ®Google Scholar
• Alkan O, Schoeberl B, Shah M, et al. Modeling chemotherapy-induced stress to identify rational combination therapies in the DNA damage response pathway. Sci Signal. 2018;11(540):eaat0229.
   PubMed Web of Science ®Google Scholar
• Ho CK, Kornaga EN, Klimowicz AC, et al. Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy. Gynecol Oncol. 2017;145(1):176–184.
   PubMed Web of Science ®Google Scholar
• Beskow C, Skikuniene J, Holgersson A, et al. Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. Br J Cancer. 2009;101(5):816–821.
   PubMed Web of Science ®Google Scholar
• Ciszewski WM, Tavecchio M, Dastych J, et al. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin. Breast Cancer Res Treat. 2014;143(1):47–55.
   PubMed Web of Science ®Google Scholar
• Lee SW, Cho KJ, Park JH, et al. Expressions of Ku70 and DNA-PKcs as prognostic indicators of local control in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2005;62(5):1451–1457.
   PubMed Web of Science ®Google Scholar
• Ihara M, Ashizawa K, Shichijo K, et al. Expression of the DNA-dependent protein kinase catalytic subunit is associated with the radiosensitivity of human thyroid cancer cell lines. J Radiat Res. 2019;60(2):171–177.
   PubMed Web of Science ®Google Scholar
• Shintani S, Mihara M, Li C, et al. Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma. Cancer Sci. 2003;94(10):894–900.
   PubMed Web of Science ®Google Scholar
• Yu S, Xiong Y, Tian S. The expression of DNA-PKcs in non-small cell lung cancer and its relationship with apoptosis associated proteins. Zhongguo Fei Ai Za Zhi. 2003;6(5):356–359.
   PubMedGoogle Scholar
• Yin Y, Li R, Xu K, et al. Androgen receptor variants mediate DNA repair after prostate cancer irradiation. Cancer Res. 2017;77(18):4745–4754.
   PubMed Web of Science ®Google Scholar
• Kotula E, Berthault N, Agrario C, et al. DNA-PKcs plays role in cancer metastasis through regulation of secreted proteins involved in migration and invasion. Cell Cycle. 2015;14(12):1961–1972.
   PubMed Web of Science ®Google Scholar
• Herrero AB, San Miguel J, Gutierrez NC. Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability. PLoS One. 2015;10(3):e0121581.
   PubMed Web of Science ®Google Scholar
• Zicari S, Sharma AL, Sahu G, et al. DNA dependent protein kinase (DNA-PK) enhances HIV transcription by promoting RNA polymerase II activity and recruitment of transcription machinery at HIV LTR. Oncotarget. 2020;11(7):699–726.
   PubMedGoogle Scholar
• Schwartz C, Rohr O, Wallet C. Targeting the DNA-PK complex: its rationale use in cancer and HIV-1 infection. Biochem Pharmacol. 2019;160:80–91.
   PubMed Web of Science ®Google Scholar
• Cooper A, García M, Petrovas C, et al. HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. Nature. 2013;498(7454):376–379.
   PubMed Web of Science ®Google Scholar
• Chung JH. The role of DNA-PK in aging and energy metabolism. Febs J. 2018;285(11):1959–1972.
   PubMed Web of Science ®Google Scholar
• Espejel S, Martín M, Klatt P, et al. Shorter telomeres, accelerated ageing and increased lymphoma in DNA-PKcs-deficient mice. EMBO Rep. 2004;5(5):503–509.
   PubMed Web of Science ®Google Scholar
• Park SJ, Gavrilova O, Brown AL, et al. DNA-PK promotes the mitochondrial, metabolic, and physical decline that occurs during aging. Cell Metab. 2017;25(5):1135–1146.e7.
   PubMed Web of Science ®Google Scholar
• Kanungo J. DNA-PK deficiency in Alzheimer’s disease. J Neurol Neuromedicine. 2016;1(3):17–22.
   PubMedGoogle Scholar
• Goldberg FW, Finlay MRV, Ting AKT, et al. The discovery of 7-methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor. J Med Chem. 2020;63(7): 3461–3471.
   PubMed Web of Science ®Google Scholar
• Yanai M, Makino H, Ping B, et al. DNA-PK Inhibition by NU7441 enhances chemosensitivity to topoisomerase inhibitor in non-small cell lung carcinoma cells by blocking DNA damage repair. Yonago Acta Med. 2017;60(1):9–15.
   PubMed Web of Science ®Google Scholar
• Harnor SJ, Brennan A, Cano C. Targeting DNA-dependent protein kinase for cancer therapy. ChemMedChem. 2017;12(12):895–900.
   PubMed Web of Science ®Google Scholar
• Pospisilova M, Seifrtova M, Rezacova M. Small molecule inhibitors of DNA-PK for tumor sensitization to anticancer therapy. J Physiol Pharmacol. 2017;68(3):337–344.
   PubMed Web of Science ®Google Scholar
• Davidson D, Amrein L, Panasci L, et al. Small molecules, inhibitors of DNA-PK, targeting DNA repair, and beyond. Front Pharmacol. 2013;4:5.
   PubMed Web of Science ®Google Scholar
• Damia G. Targeting DNA-PK in cancer. Mutat Res Fund Mol Mech Mutagen. 2020;821:111692.
   PubMed Web of Science ®Google Scholar
• Kudos Pharm Ltd. and Cancer Rec. Tech Ltd. . Dibenzothiophene derivatives as DNA-PK inhibitors.WO 2010136778; 2010.
   Google Scholar
• Merck Patent Gmbh. Morpholinylquinazolines. WO 2011113512; 2011.
   Google Scholar
• Merck Patent Gmbh. Morpholinylbenzotriazine for use in cancer therapy. WO 2013072015; 2013.
   Google Scholar
• Merck Patent Gmbh. Arylquinazolines.WO 2014183850; 2014.
   Google Scholar
• Sun Q, Guo Y, Liu X, et al. Therapeutic implications of p53 status on cancer cell fate following exposure to ionizing radiation and the DNA-PK inhibitor M3814. Mol Cancer Res. 2019;17(12):2457–2468.
   PubMed Web of Science ®Google Scholar
• Merck Patent Gmbh. Pyrazolo-quinolines. WO 2012000632; 2012.
   Google Scholar
• Merck Patent Gmbh. Imidazo[4,5-c]quinolones as DNA-PK inhibitors. WO 2012028233; 2012.
   Google Scholar
• Eli Lilly and Barda David Anthony; Co. Imidazo[4,5-c]quinolin-2-one compound and its use as PI3K kinase/mTOR dual inhibitor. WO 2012097039; 2012.
   Google Scholar
• Smith MC, Mader MM, Cook JA, et al. Characterization of LY3023414, a novel PI3K/mTOR dual inhibitor eliciting transient target modulation to impede tumor growth. Mol Cancer Ther. 2016;15(10):2344–2356.
   PubMed Web of Science ®Google Scholar
• Zha S, Jiang W, Fujiwara Y, et al. Ataxia telangiectasia-mutated protein and DNA-dependent protein kinase have complementary V(D)J recombination functions. Proc Natl Acad Sci USA. 2011;108(5):2028–2033.
   PubMed Web of Science ®Google Scholar
• Xrad Therapeutics Inc. and Wang Yaode. Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy. WO 2019201283; 2019.
   Google Scholar
• Vertex Pharma. DNA-PK inhibitors .WO 2013163190; 2013.
   Google Scholar
• Vertex Pharma. Co-crystals of (S)-N-methyl-8-(1-((2ʹ-methyl-[4,5ʹ-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as DNA-PK inhibitors .WO 2015058067; 2015.
   Google Scholar
• Boucher D, Hoover R, Wang Y, et al. Abstract 3716: potent radiation enhancement with VX-984, a selective DNA-PKcs inhibitor for the treatment of NSCLC. The 107th Annual Meeting of the American Association for Cancer Research (AACR); April 16–20, 2016; New Orleans, LA, (USA).
   Google Scholar
• Vertex Pharma. DNA-PK inhibitors. WO 2015058031; 2015.
   Google Scholar
• Vertex Pharma. DNA-PK inhibitors. WO 2014159690; 2014.
   Google Scholar
• Vertex Pharma. DNA-PK inhibitors. WO 2019143678; 2019.
   Google Scholar
• Vertex Pharma. DNA-PK inhibitors. WO 2019143675; 2019.
   Google Scholar
• Vertex Pharma. Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency. WO 2019143677; 2019.
   Google Scholar
• AstraZeneca AB and Cancer Research Tech. Ltd. Amino-triazolopyridine compounds and their use in treating cancer. WO 2018114999; 2018.
   Google Scholar
• AstraZeneca AB and Cancer Research Tech. Ltd. Amino-triazolopyridine compounds and their use in treating cancer. CN 110177791; 2019.
   Google Scholar
• AstraZeneca AB 2-Anilinopurin-8-one derivatives as TTK/MPS1 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of proliferative disorders. WO 2009024824; 2009.
   Google Scholar
• AstraZeneca AB and Cancer research Tech. LTD. Purinone compounds and their use in treating cancer. WO 2019238929; 2019.
   Google Scholar
• Celgene Corp. and Univ. Michigan Regents. Treatment of cancer with DNA-PK inhibitors. WO 2016210046; 2016.
   Google Scholar
• Tsuji T, Sapinoso LM, Tran T, et al. CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro. Oncotarget. 2017;8(43):74688–74702.
   PubMedGoogle Scholar
• Raymon H, Peng S, Katz J, et al. Antitumor activity of mTOR kinase and DNA-PK inhibitor CC-115 in a mouse model of glioblastoma. Eur J Cancer. 2014;50(6):170.
   PubMedGoogle Scholar
• Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds. WO 2019222272; 2019.
   Google Scholar
• Nankai Univ. Preparation method and application of pyrazino[2,3-c]quinoline-2(1H)-one compounds used as mTOR inhibitors. CN 108948003; 2017.
   Google Scholar
• Beaufils F, Cmiljanovic N, Cmiljanovic V, et al. 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-Class I PI3K/mTOR inhibitor as clinical candidate in oncology. J Med Chem. 2017;60(17):7524–7538.
   PubMed Web of Science ®Google Scholar
• Brown JS, O’Carrigan B, Jackson SP, et al. Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov. 2017;7(1):20–37.
   PubMed Web of Science ®Google Scholar
• Willers H, Dahm-Daphi J, Powell SN. Repair of radiation damage to DNA. Br J Cancer. 2004;90(7):1297–1301.
   PubMed Web of Science ®Google Scholar
• Sorensen M, van Bussel M, Kuipers M, et al. Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: results from two phase I trials. Ann Oncol. 2018;29(sup8):viii654.
   Google Scholar
• Mortensen DS, Perrin-Ninkovic SM, Shevlin G, et al. Optimization of a series of triazole containing mammalian target of rapamycin (mTOR) kinase inhibitors and the discovery of CC-115. J Med Chem. 2015;58(14):5599–5608.
   PubMed Web of Science ®Google Scholar
• Munster P, Mita M, Mahipal A, et al. First-In-Human phase i study of a dual mTOR kinase and DNA-PK inhibitor (CC-115) In advanced malignancy. Cancer Management and Research. 2020;821:10463–10476.
   Google Scholar
• Fok JHL, Ramos-Montoya A, Vazquez-Chantada M, et al. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nat Commun. 2019;10(1):5065.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Varghese AM, Hyman DM, et al. A first-in-human phase 1 study of LY3023414, an oral PI3K/mTOR dual inhibitor, in patients with advanced cancer. Clin Cancer Res. 2018;24(14):3253–3262.
   PubMed Web of Science ®Google Scholar
• Wen PY, Omuro A, Ahluwalia MS, et al. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro Oncol. 2015;17(9):1275–1283.
   PubMed Web of Science ®Google Scholar
• A E G, Stocks MJ. Class 1 PI3K clinical candidates and recent inhibitor design strategies: A medicinal chemistry perspective. J Med Chem. 2019;62(10):4815–4850.
   PubMed Web of Science ®Google Scholar
• Maréchal A, Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol. 2013;5(9):a012716.
   PubMed Web of Science ®Google Scholar
• Rossello X, Riquelme JA, He Z, et al. The role of PI3Kα isoform in cardioprotection. Basic Res Cardiol. 2017;112(6):66.
   PubMed Web of Science ®Google Scholar
• Cano C, Saravanan K, Bailey C, et al. 1-Substituted (dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity. J Med Chem. 2013;56(16):6386–6401.
   PubMed Web of Science ®Google Scholar
• Finlay MRV, Griffin RJ. Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family. Bioorg Med Chem Lett. 2012;22(17):5352–5359.
   PubMed Web of Science ®Google Scholar
• Baretic D, Maia de Oliveira T, Niess M, et al. Structural insights into the critical DNA damage sensors DNA-PKcs, ATM and ATR. Prog Biophys Mol Biol. 2019;147:4–16.
   PubMed Web of Science ®Google Scholar